Vivos Therapeutics, Inc. (VVOS) has a negative trailing P/E of -0.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -128.40%.
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -12.2 | 0.00 | 21.51 | 27.38 | - |
| 2019 | -10.4 | -0.56 | -37.91 | 9.79 | - |
| 2020 | -8.9 | -0.71 | 6.36 | 8.24 | - |
| 2021 | -2.4 | 0.72 | 1.87 | 2.83 | - |
| 2022 | -0.4 | -0.05 | 1.93 | 0.58 | - |
| 2023 | -1.1 | 0.02 | 36.91 | 1.10 | - |
| 2024 | -1.9 | 0.02 | 2.71 | 1.43 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-18.49 | $3.79M | $-8.54M | -225.3% |
| 2019 | $-21.94 | $11.39M | $-10.89M | -95.6% |
| 2020 | $-12.11 | $13.07M | $-8.82M | -67.5% |
| 2021 | $-23.89 | $16.89M | $-20.29M | -120.2% |
| 2022 | $-24.62 | $16.02M | $-22.66M | -141.4% |
| 2023 | $-11.14 | $13.8M | $-13.58M | -98.4% |
| 2024 | $-1.68 | $15.03M | $-11.14M | -74.1% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.85 | $-0.88 – $-0.79 | $30.78M | $30.63M – $30.92M | 2 |
| 2027 | $0.00 | $0.00 – $0.00 | $52.15M | $49.32M – $53.4M | 0 |
